OMER News and Press, Omeros Corporation From 02/03/20

Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test now using the top four forensic algorithms applied to detect bankruptcy risk, earnings manipulation, and financial irregularities. This forward testing study co...

In late August, we first published on OCUL citing it as a deep value opportunity, with the stock skewed toward significant upside as we expect the launch of the company's Dextenza product to be impressive. Our view remains unchanged, and we believe that the thesis remains intact and is mater...

myTomorrows, a global health technology company, and Omeros Corporation (Nasdaq: OMER), an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics, today announced a collaboration. The collaboration broadens Omeros&...

Omeros Corporation (Nasdaq: OMER) last week presented new data directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology (ESMO) 2019 Immuno-Oncology Congress in Geneva, Switzerland. In addition to previously reported findings, which revealed enhance...

Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated ...

Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology 2019 Immuno-Oncology Congress, which is being held December 11-14, 2019 in Geneva, Switzerland. In addition to p...

Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020. This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA. This is in no way a thorou...

Omeros (OMER) reported positive results for OMS721 or narsoplimab, an anti-MASP-2 antibody that Omeros plans to use in HSCT-associated thrombotic microangiopathy, or HSCT-TMA, a potentially fatal complication of using stem cells to treat hematological malignancies. The treatment achieved 100 d...

Shares of Omeros   (NASDAQ: OMER) , a biopharmaceutical company, are losing ground after the company announced an unenthusiastic price for shares to be offered in a secondary offering. As of 11:49 a.m. EST, the stock has fallen 11.9% from its previous close. Since Omeros is going t...

Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated ...